Everolimus has been approved by the US Food and Drug Administration (FDA) as the first oral, daily therapy (5 mg and 10 mg tablets) to treat advanced kidney cancer after failure of treatment with sunitinib or sorafenib. New data demonstrate that treatment with Afinitor ® (everolimus) in combination with Sandostatin® LAR® (octreotide acetate suspension for injection) and Afinitor monotherapy may have the potential to stabilize tumour growth in patients with advanced pancreatic neuroendocrine tumours (NET). These results were presented at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The final analysis shows that patients with progressive disease who received everolimus in combination with octreotide, an approved treatment for symptom control in certain types of NET, had a median progression-free survival period of 16.7 months; 4% of these patients had a partial response and 78% had stable disease. For patients who took everolimus as monotherapy, the median progression-free survival was 9.7 months, 8% of these patients had a partial response and 69% had stable disease.
Yao, et al. A Phase II Trial of Daily Oral RAD001 (Everolimus) in Patients With Metastatic Pancreatic Neuroendocrine Tumours (NET) After Failure of Cytotoxic Chemotherapy. 33rd European Society for Medical Oncology Congress, Stockholm, Sweden.